Pre-clearance

United Kingdom ／ MHRA / PMCPA

The MHRA has statutory powers to require companies to submit advertising material for pre-publication vetting, has committed as a matter of policy to vet initial advertising for all new active substances, and applies vetting for a period that is normally one to three months and normally no longer than six months.

MHRAは広告資材の発行前提出（vetting）を求める法的権限を持ち、新有効成分の初回広告はすべて審査する方針で、対象期間は通常1〜3か月、通常6か月を超えない。

regulator guidanceMHRA, The Blue Guide: Advertising and Promotion of Medicines in the UK, Third Edition, chapter 8.2checked 2026-09-23

Note
Other circumstances listed are reclassification (e.g. POM to P) and previous breaches. The Blue Guide states the MHRA is not able to provide a routine vetting service on request. Separate industry pre-vetting exists under PAGB and PMCPA codes and under Clearcast/Radiocentre for broadcast. MHRA's operational guidance (Vetting Guidance, updated June 2023, https://assets.publishing.service.gov.uk/media/64871ce35f7bb700127fa878/Vetting_Guidance_Updated_June_2023.pdf) requires a minimum of three weeks' notice for the initial submission and one item at a time.

The same topic elsewhere

Japan ── Sales information materials must be reviewed before use by an in-house promoti…United States ── An applicant must submit specimens of promotional labeling and advertising at …Canada ── Preclearance of advertising for marketed health products is administered throu…European Union ── Member States must ensure that there are adequate and effective methods to mon…China ── Advertisements for medical services, drugs and medical devices must be reviewe…Australia ── Use of a restricted representation, that is one referring to a serious form of…Korea ── A manufacturer, marketing authorisation holder or importer that intends to adv…Switzerland ── Switzerland has no across-the-board pre-vetting scheme: prior authorisation by…